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Off Label Innovation:
Discovering New Uses for Glaucoma Drops
By Glenn Oh, BS | Faculty Mentor: Jason Hsu, MD

Neovascular
age-related
macular
degeneration (nAMD) is a common retinal
disease that is the leading cause of blindness
in the United States.1 Neovascularization
is the process of uncontrolled, progressive
growth of aberrant blood vessels in the
back of the eye. These weak vessels can
leak intravascular fluid that may ultimately
damage the macula, the central area of the
retina that is responsible for sharp, central,
color vision. Intravitreal administration of
anti-vascular endothelial growth factor
(anti-VEGF) agents is currently the gold
standard treatment to reduce the growth
of and leakage from new blood vessels,
thereby slowing nAMD progression.1
Most clinicians follow a treat and
extend protocol when injecting anti-VEGF
drugs.2 Patients are typically initiated on
injections at monthly intervals. Once the
edema is under control, the injection
intervals are gradually increased until
signs of exudation recur, at which point
the next interval is decreased to the prior
interval without exudation. This protocol
generally helps to minimize the number
of injections for patients while maximizing
visual outcomes, and the average patient
typically ends up requiring injections
approximately every 2 - 3 months for
maintenance once stabilized.3,4 However,
some patients have a suboptimal response
to the currently available anti-VEGF drugs
and demonstrate persistent exudation

despite frequent injections at 4 - 6 week
intervals.
A few studies suggest that anti-VEGF
injections are cleared through aqueous
humor outflow in the anterior chamber
of the eye.6-8 As a result, it has been
hypothesized that reducing aqueous
humor production may reduce fluid and
drug turnover inside the eye, allowing antiVEGF agents to have a longer duration of
effect.6-8 Dr. Jason Hsu worked on a case
series in which patients with nAMD who
were suboptimal responders to anti-VEGF
had less signs of exudation after being
started on topical dorzolamide-timolol,
a carbonic-anhydrase inhibitor and
beta-blocker combination used to treat
glaucoma.9 Dorzolamide-timolol has a
potent effect on reducing aqueous humor
production by 50%, and its components
may also downregulate VEGF production.
In addition, some studies have shown that
its components may help reduce cystoid
macular edema and increase retinal
perfusion and oxygenation that could
further benefit patients with nAMD.10-15
Dr. Jason Hsu and his team (Ophthalmic
Consultants
of
Boston,
Boston,
Massachusetts; Retinal Consultants of
Houston, Houston, Texas; Retina Service
of Wills Eye Hospital and Mid Atlantic
Retina,
Philadelphia,
Pennsylvania;
Associated Retinal Consultants, Royal
Oak, Michigan) performed a multicenter
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randomized placebo-controlled clinical
trial in which patients with nAMD who were
suboptimal responders despite frequent
anti-VEGF injections were randomized
to use either dorzolamide-timolol drops
or artificial tears.16 Eligible patients were
45 years or older with nAMD who were
receiving ranibizumab or aflibercept
injections at 4 - 6 week intervals (i.e., at
least four injections within six months
prior to enrollment) and had evidence of
persistent exudation, which was defined
as intraretinal or subretinal fluid on optical
coherence tomography (OCT). They must
have received the same anti-VEGF agent
for two consecutive visits with an injection
interval of 4 - 6 weeks. Finally, the patients
needed a baseline central subfield
thickness (CST) of at least 270 µm on OCT.
Sixty-three eligible patients were
subsequently randomized to the twicedaily treatment of dorzolamide-timolol
or to the placebo of artificial tears.
The physicians and study coordinators
were blinded. OCT, visual acuity, and
intraocular pressure (IOP) measurements
were taken at each of the three visits. The
primary outcome was change in CST, an
automated measurement that represents
the average macular thickness within
a 1 mm circle centered on the fovea.
Secondary outcomes included changes
in maximum subretinal fluid height (SRF),
maximum pigment epithelial detachment
(PED), central foveal thickness (CFT),
central subfoveal fluid height (CFF), mean
visual acuity, and IOP. There were 27
patients in the experimental group and 23
in the placebo group that completed the
third visit after three months in the study.
Regarding anatomical outcomes, the
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study showed significant improvements
in mean CST and maximum PED height.
Changes in maximum SRF height, CFT, and
central SFF height were not significant.
Changes in logMAR visual acuity and
IOP were also not significant. The study
concluded that topical dorzolamidetimolol treatment in nAMD patients with
persistent exudation reduced macular
edema but did not significantly change
visual acuity. Perhaps more research on
the clinical relevance of these anatomical
changes or a longer study duration may
better illustrate the effects of dorzolamidetimolol on nAMD. Through this study’s
use of randomization, a control group,
and blinding, it effectively builds on the
growing literature of case reports and
non-randomized trials using dorzolamidetimolol drops as an adjunct to anti-VEGF
therapy for patients with nAMD. Thus,
it can be concluded that dorzolamidetimolol’s use as an adjunctive therapy is
effective for reducing macular edema in
the treatment of nAMD.
When we interviewed Dr. Hsu on the
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development of this study, he explained
that the first patient who benefited from the
use of glaucoma drops was a colleague with
a history of anti-VEGF injections. Almost
immediately after initiation of the adjuvant
therapy, Dr. Hsu observed a significant
amount of fluid reduction. As a result, a
pilot study was initiated and, based on the
promising results, led to the multicenter
randomized clinical trial. I found this
clinical trial especially interesting because
it highlighted a medical innovation in
an unexpected way. Discovering new
techniques or pharmacologic therapies is
clearly important for medical progress, but
finding alternative uses and maximizing
the potential of existing therapies is
equally innovative. Retinal diseases,
including nAMD, often do not consider
topical therapy. Dr. Hsu and his team’s
use of topical dorzolamide-timolol is a
noteworthy innovation that will make an
impact on many patients suffering with
nAMD.
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